Key Takeaways:

  • The FDA sent 30 warning letters to telehealth companies for illegally marketing compounded GLP-1s
  • Companies were "mass marketing" their products as similar alternatives to FDA-approved drugs like Wegovy, Ozempic, Mounjaro, and Zepbound
  • Compounded drugs are not FDA-approved, which means the agency does not review their safety, effectiveness or quality before they are marketed
  • Real patients are paying hundreds of dollars for treatments that may not work as expected

The FDA has launched its most aggressive enforcement action yet against telehealth companies selling compounded GLP-1 medications, sending 30 warning letters to companies for illegally marketing compounded GLP-1s with misleading claims.

The crackdown, announced this week, represents a significant escalation in the agency's efforts to protect people from potentially dangerous weight loss treatments being sold online without proper oversight.

The FDA's Enforcement Action

On March 2, the FDA announced it sent 30 letters to telehealth companies for making "false or misleading claims" regarding compounded GLP-1 products offered on their websites. The action targets companies that have been capitalizing on the massive demand for weight loss medications like semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (found in Zepbound and Mounjaro).

"It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action," FDA Commissioner Marty Makary, M.D., M.P.H. said. "Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not try to compound drugs in a way that circumvents FDA's approval process."

The warning letters specifically call out companies for "mass marketing" their GLP-1s as similar alternatives to FDA-approved drugs, claiming their products contain the same active ingredient as Wegovy, Ozempic, Mounjaro, and Zepbound.

What Makes These Claims Problematic

The core issue isn't that compounded medications exist — they serve an important role in healthcare. Compounding is the practice of combining, mixing, or altering drug ingredients to create a medication tailored to an individual person's needs. Compounded drugs may be used when an FDA-approved medication is not suitable due to someone's unique circumstances, as well as when approved drugs are in short supply.

The problem lies in how these companies are marketing their products. Compounded drugs are not FDA-approved, which means the agency does not review their safety, effectiveness or quality before they are marketed. Compounded drugs are also not the same as generic drugs, which are FDA-approved.

When telehealth companies present these compounded versions as equivalent alternatives to FDA-approved medications, they're essentially promising the same benefits without the same regulatory oversight and quality guarantees.

Real-World Impact: What People Are Experiencing

The enforcement action comes as real people are experiencing the consequences of these misleading claims. Take Tanar Frankl, a Greenwood, Indiana mother who lost her insurance coverage while taking Zepbound.

Desperate to not regain what she lost, Frankl went online and started researching telehealth GLP-1s. The process was remarkably simple — she never talked to a doctor, describing it as "strangely easy." She paid $800 for a 6-month supply of semaglutide.

She didn't realize she was injecting an unapproved version of a GLP-1 until reporters explained what she bought online. The compounded version hasn't worked: "It's not doing anything," she said. "I'm wasting my time is how it feels."

Frankl's experience highlights exactly why the FDA is concerned. People are paying significant amounts of money for treatments that may not work as expected, all while believing they're getting the same medication their doctor originally prescribed.

The Broader Regulatory Landscape

This enforcement action is part of a larger regulatory tightening around GLP-1 compounding. The FDA announced Friday that it intends to restrict the active pharmaceutical ingredients of glucagon-like peptide-1 (GLP-1) receptor agonists used in unapproved compounded drugs that are being mass-marketed as alternatives to approved medications.

The agency has also clarified its "four prescription limit" policy, stating that it won't take enforcement action against compounding pharmacies that fill four or fewer prescriptions per month of compounded GLP-1 copies. This creates a clear distinction between individualized care and mass-market operations.

The green list, issued by the Center for Drug Evaluation and Research (CDER), provides a collection of compounders that have acceptable standards and use APIs from FDA-inspected facilities. "By strengthening oversight of imported APIs and cracking down on illegal drugs entering the U.S., we are taking aggressive action to protect consumers from poor-quality or dangerous GLP-1 drugs," FDA Commissioner Marty Makary said.

What This Means for You

If you're considering GLP-1 treatment for weight loss, this crackdown actually creates clearer pathways to safe, effective care. The FDA's actions help distinguish between legitimate medical care and questionable online offerings.

When evaluating your options, focus on working with healthcare providers who can prescribe FDA-approved medications and provide proper medical supervision. While compounded medications can play a role in treatment when there's a specific medical need, be wary of any service that positions their compounded products as simple substitutes for brand-name drugs.

The enforcement action also underscores the importance of comparing costs across legitimate channels rather than gravitating toward the cheapest online option. With new pricing programs and expanded access initiatives, FDA-approved treatments are becoming more affordable through proper medical channels.

For those seeking treatment, finding a qualified provider who can navigate both FDA-approved options and legitimate compounding when medically necessary remains your best path to safe, effective weight loss treatment. The FDA's crackdown ultimately serves to protect you from paying for treatments that may not work while ensuring access to medications that do.